Astellas Pharma Europe Ltd.

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics DUNDEE, Scotland--(BUSINESS WIRE)-- Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna). Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna. The DUB enzymes regulate ubiquitination in the ubiquitin-proteasome system (UPS). Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics. Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes in the fields of protein degradation, stabilisation and cellular signalling. Ubiquigent has an established specialised drug discovery platform and long-standing expertise in the exploitation of the DUBs for therapeutic benefit. The platform can be applied to support the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs across any therapeutic area. Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics. Our platform was established to support those seeking to modulate DUB activity for therapeutic benefit and has been used by a long list of global partners which we are very pleased to add Nanna Therapeutics to.” To learn more about Ubiquigent’s discovery and development platform, please visit . View source version on businesswire.com: Contacts Esmé Walters Zyme Communications E-mail: esme.walters@zymecommunications.com Phone: +44 (0) 7377 543244 Source: Ubiquigent View this news release online at:

Supports ambitious commercialisation strategy for DNA synthesis platform, gSynth Follows $10m Series A financing to scale operations CAMBRIDGE, England--(BUSINESS WIRE)-- Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors. Following its $10 million Series A financing earlier in the year1, the appointment forms part of the Company’s growth plans to expand commercialisation of its pioneering DNA synthesis platform, gSynth™. Nicola is an industry leader, with experience developing and commercialising innovative technologies and therapeutic modalities. She was the founding CEO of Amphista Therapeutics, successfully steering the company through a $7.5 million Series A, a $53 million Series B and established partnerships with leading pharmaceutical companies with a combined deal value of more than $2 billion. Prior to Amphista, she was Chair of the Board at Nanna Therapeutics, playing a key role in corporate development and its successful acquisition by Astellas. Nicola also held senior leadership roles at Roche, where she built and led pRED’s external drug discovery organisation, and in business development at GSK. Nicola received a PhD in Cell Biology from University College London. Dr Steve Harvey, CEO, Camena Bioscience commented: "Nicola is a successful CEO and Chair and a fantastic addition to the Board. Camena Bioscience enables researchers to ‘write’ DNA with the same confidence and ease with which we can ‘read’ DNA. Our highly accurate DNA synthesis technology, called gSynth, provides access to gene sequences that scientists previously could not obtain. This accelerates our customers' discovery timelines and allows them to produce potentially new therapeutics they previously couldn't. With Pharma's increased focus and collective commitment to decarbonising health systems, Camena is leading the way with a green synthesis technology focused on reducing waste associated with traditional DNA synthesis methods. Our proposition is disrupting the existing DNA synthesis market." Dr Nicola Thompson, Chair of the Board, Camena Bioscience, added: “I am delighted to join the Company as its Chair at this pivotal stage of growth. The leadership team are recognised pioneers in the field and the existing Board has an impressive array of investment and entrepreneurial experience, which will collectively support Camena on their scale-up journey. Camena has a uniquely differentiated technology to address the limitations of traditional DNA synthesis approaches and I'm looking forward to working with the team, executing on Camena's mission to build the leading DNA synthesis company." Press release (3rd July, 2023): Camena Bioscience close $10m Series A financing as demand for DNA synthesis technology increases ENDS View source version on businesswire.com: Contacts Zyme Communications Katie Odgaard Tel: +44(0) 7787 502 947 Email: katie.odgaard@zymecommunications.com Source: Camena Bioscience View this news release online at:

TORRANCE, Calif., Nov. 27, 2023 /PRNewswire/ -- Sunrider International, a global leader in nutrition, health, and personal wellness products, is pleased to announce the appointment of Mr. Sam Lee as the new General Manager of Sunrider China. With a career that spans over two decades in the direct selling industry and government relations, Mr. Lee brings a wealth of experience to his new role, which will be instrumental in driving the company's growth and success in the Chinese market. Mr. Lee graduated from the Civil and Environmental Engineering department at Tsinghua University in 1990. Over the years, he has held various positions in government, media, and the direct selling industry, making him a well-rounded and accomplished professional. Mr. Lee's career began in local government and state-owned media, and he then become a senior investment promotion government official and division chief of the Suzhou Industrial Park Administrative Committee, a China-Singapore joint development zone. In 2000, Mr. Lee obtained an EMBA diploma from the National University of Singapore. Following this achievement, he joined Herbalife (China) Co., where he spent five years as a senior manager for sales and operations, as well as government affairs. He also served as the Chief Representative of Herbalife Beijing office. In 2006, Mr. Lee joined Shaklee (China), where he played a pivotal role in the company's setup, factory construction, team hiring, and market expansion in China. Over the years, he assumed various roles within the company, serving as Marketing Director, Deputy General Manager, and Senior Vice President, culminating in his appointment as President of Shaklee (China). From October 2019, Mr. Lee also served local healthcare companies, namely Jimon Group and VV Health, as CEO and President, demonstrating his versatility and ability to excel in diverse business environments. Beyond his professional accomplishments, Sam Lee has also made significant contributions to various non-governmental organizations (NGOs). He has served as the Director of the China Foundation for Justice and Courage and as the Vice Chairman of the Beijing Healthcare Association. In his new role as the General Manager of Sunrider China, Sam Lee will oversee all aspects of Sunrider China's operations, including sales, marketing, training, and finance teams. He will also work closely with the Sunrider Manufacturing team to coordinate product inventory and new product launches. Mr. Lee said this about his new role with Sunrider: "I'm excited to embark on this journey with Sunrider, a true legend and innovation leader in the China market, with this December marking the company's 30th anniversary in the country." My goals include refining our business model, enhancing the total customer experience, and empowering our market leaders and sales force through enhanced branding and training. Together, we'll take Sunrider to new heights in China." Sunny Beutler, Sunrider CEO, said this about Mr. Lee's appointment: "As a seasoned manager, Mr. Lee possesses extensive experience in business expansion, brand marketing, communication, and profit management. Under his leadership, we anticipate a fresh development phase for Sunrider China." About Sunrider International Sunrider International, a direct selling and retail sales company, was founded in 1982 by Drs. Tei-Fu and Oi-Lin Chen. All five of Drs. Chen's adult children hold senior executive positions within the multi-generational family-owned company, either directly at the corporate headquarters or on the Board of Directors. Their passion for people led them to create proven herbal products that help others achieve optimal health and wellness, and a business plan that offers them the opportunity to live happier, more balanced lives. Guided by owner expertise, Sunrider is a growing global enterprise that currently spans nearly 50 countries and regions. SOURCE Sunrider International